Amneal Pharmaceuticals, Inc. Class A

XNASHealth care

Last traded price · USD

$19.95

−1.29%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:25 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $20.21
Volume: 7.2M
Day's high: —
Day's low: —

In brief

Amneal Pharmaceuticals, Inc. is a health care company listed on Nasdaq, valued at about $6.95B.
Its shares closed at $19.95 on 4 Nov 2026, up 75.8% over the past year.
From India you can buy AMRX in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Amneal Pharmaceuticals, Inc. (AMRX) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole AMRX share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade AMRX options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: −1.7% (SPY −1.6%, XLV +13.5%). 3 months: +8.1% (SPY −0.4%, XLV +15.5%). 1 year: +75.8% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: AMRX, SPY and XLV · as of 4 Nov 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $19.95 was 3.6% above its 50-day average ($19.26) and 25.9% above its 200-day average ($15.85). It has closed above the 200-day for 117 sessions, since 20 May 2026. The 50-day average crossed above the 200-day on 13 Aug 2025, 309 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
83% of the way up its 52-week range
Closed at $19.95 on 4 Nov 2026: 8.0% below the 52-week high of $21.68 (2 Nov 2026) and 76.6% above the low of $11.29 (7 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026
Volume 1.9× its 30-session average on 4 Nov 2026
4 Nov 2026 volume of 7.2M shares was 1.9× the average of the 30 sessions before it (3.9M), as the price fell 1.3%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026
Short interest at 4.4% of shares outstanding
14.1M shares were sold short at the 15 Oct 2026 settlement, 4.4% of the 319.4M shares outstanding; covering them would take 3.7 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−1.7%

6 months+46.5%

1 year+75.8%

5 years+291.9%

Newswire

About

Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

Website

Notable moves

October 24, 2023
+19.05%
August 4, 2023
+22.32%
April 17, 2023
+21.32%

Newswire

About

Website

Notable moves

October 24, 2023
+19.05%
August 4, 2023
+22.32%
April 17, 2023
+21.32%

Amneal Pharmaceuticals, Inc. Class A

XNASHealth care

Last traded price · USD

$19.95

−1.29%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:25 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $20.21
Volume: 7.2M
Day's high: —
Day's low: —

In brief

Amneal Pharmaceuticals, Inc. is a health care company listed on Nasdaq, valued at about $6.95B.
Its shares closed at $19.95 on 4 Nov 2026, up 75.8% over the past year.
From India you can buy AMRX in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Amneal Pharmaceuticals, Inc. (AMRX) shares from India?

Do I need the price of a whole AMRX share to invest?

How much can I invest in US stocks in a year?

Can I trade AMRX options or futures?

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: −1.7% (SPY −1.6%, XLV +13.5%). 3 months: +8.1% (SPY −0.4%, XLV +15.5%). 1 year: +75.8% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: AMRX, SPY and XLV · as of 4 Nov 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $19.95 was 3.6% above its 50-day average ($19.26) and 25.9% above its 200-day average ($15.85). It has closed above the 200-day for 117 sessions, since 20 May 2026. The 50-day average crossed above the 200-day on 13 Aug 2025, 309 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
83% of the way up its 52-week range
Closed at $19.95 on 4 Nov 2026: 8.0% below the 52-week high of $21.68 (2 Nov 2026) and 76.6% above the low of $11.29 (7 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026
Volume 1.9× its 30-session average on 4 Nov 2026
4 Nov 2026 volume of 7.2M shares was 1.9× the average of the 30 sessions before it (3.9M), as the price fell 1.3%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026
Short interest at 4.4% of shares outstanding
14.1M shares were sold short at the 15 Oct 2026 settlement, 4.4% of the 319.4M shares outstanding; covering them would take 3.7 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−1.7%

6 months+46.5%

1 year+75.8%

5 years+291.9%

Newswire

About

Website

Notable moves

October 24, 2023
+19.05%
August 4, 2023
+22.32%
April 17, 2023
+21.32%

Newswire

About

Website

Notable moves

October 24, 2023
+19.05%
August 4, 2023
+22.32%
April 17, 2023
+21.32%

Amneal Pharmaceuticals, Inc. Class A

Amneal Pharmaceuticals, Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

Above its 50- and 200-day averages

83% of the way up its 52-week range

Volume 1.9× its 30-session average on 4 Nov 2026

Short interest at 4.4% of shares outstanding

Amneal Pharmaceuticals, Inc. Class A

Amneal Pharmaceuticals, Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

Above its 50- and 200-day averages

83% of the way up its 52-week range

Volume 1.9× its 30-session average on 4 Nov 2026

Short interest at 4.4% of shares outstanding